MabVax Therapeutics Holdings, Inc. (MBVX)

Oncology Corporate Profile

Stock Performance

0.0000
0.0000

3 Month Stock History Chart

HQ Location

11588 Sorrento Valley Road Suite 20
San Diego, CA 92121

Company Description

MabVax Therapeutics Holdings, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. MabVax has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center. MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma ready for Phase II clinical development.

Website: http://www.mabvax.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
MVT-1075radioimmunotherapyColorectal cancerI
MVT-1075radioimmunotherapyPancreatic cancerI
MVT-5873monoclonal antibodyPancreatic cancerI
MVT-2163radioimmunotherapyPancreatic cancerI
MVT-1075radioimmunotherapySmall Cell Lung Cancer (SCLC)I
HuMab 5B1antibody drug conjugates (ADC)Pancreatic cancerPreclinical

View additional information on product candidates here »

Source: http://www.mabvax.com/

Recent News Headlines

There are no news items to display